Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
Public ClinicalTrials.gov record NCT00529399. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects
Study identification
- NCT ID
- NCT00529399
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- GAD-Alum Drug
- GAD-Alum and Aluminum hydroxide Drug
- Aluminum hydroxide Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Apr 30, 2012
- Completion
- Apr 30, 2012
- Last update posted
- May 6, 2020
2009 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital of Los Angeles | Los Angeles | California | 90027 | — |
| Stanford University | Palo Alto | California | 94305 | — |
| University of California-San Francisco | San Francisco | California | 94143 | — |
| Barbara Davis Center for Childhood Diabetes/University of Colorado Health Sciences Center | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| University of Florida | Gainesville | Florida | — | — |
| University of Miami/ Miller School of Medicine | Miami | Florida | 33136 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Columbia University | New York | New York | 10032 | — |
| Childrens Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| University of Texas/Southwestern Medical School | Dallas | Texas | 75390-8858 | — |
| Benaroya Research Institute | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00529399, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00529399 live on ClinicalTrials.gov.